FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

vvasimigton, D.O. Lot

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

	tions may conti ction 1(b).	nue. <i>See</i>		Filed								rities Exchan ompany Act					hours per r	espons	se:	0.5
1. Name and Address of Reporting Person* ORBIMED ADVISORS LLC				2. Issuer Name and Ticker or Trading Symbol ScPharmaceuticals Inc. [SCPH] 5. Relationship (Check all applications) Direct											blicable	•				
(Last) (First) (Middle) 601 LEXINGTON AVENUE, 54TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 05/21/2020									Officer (give title Other (specify below) below)						
(Street) NEW YORK NY 10022-4629					4. 1	Line) Form filed										i filed b	nt/Group Filing (Check Applicable d by One Reporting Person d by More than One Reporting			
(City)	(St		Zip)		4:															
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Date		te,	3. Transa	3. Transaction Code (Instr.		4. Securities Acquir Disposed Of (D) (Ins 5)		l (A) or	5. Amount of Securities Beneficially Owned Following	of	Form: Di (D) or	Indirect (I)		ire of et cial ship 4)			
									Code V		mount	(A) or (D)	Price	Reported Transaction (Instr. 3 and	(s) 4)					
Common	Stock			05/21/2020					P		1	,156,083	A	\$8.65	4,565,9	4,565,948			See Footnotes ⁽¹⁾⁽²⁾	
Common	nmon Stock 05/21/2020)			P		Ī	231,200 A		\$8.65	231,200		I		See Footnotes ⁽²⁾⁽³⁾		
		Tal	ble I	I - Derivati (e.g., pu												d				
1. Title of Derivative Security (Instr. 3)			rivative curities quired or sposed (D) str. 3, 4			tercisable and 7. Title and Amount of		le and unt of rities erlying rative rity (Instr	8. Price of Derivative Security (Instr. 5) Bene Own		urities eficially ned owing orted nsaction(s) Fori		nership m: Benefici ctt (D) Owners ndirect (Instr. 4)							
					Code	e V	(A)) (Da D) Ex	ite ercisa	able	Expiration Date	Title	Amoun or Numbe of Shares						
		Reporting Person*	<u>.</u>																	
(Last) 601 LEX		(First) AVENUE, 54TH	•	Middle)																
(Street)	ORK	NY	1	10022-4629																
(City)		(State)	(Zip)																
1. Name a	nd Address of	Reporting Person*																		

(Street) NEW YORK NY 10022-4629 (City) (State) (Zip) 1. Name and Address of Reporting Person* OrbiMed Capital GP VI LLC (Last) (First) (Middle) 601 LEXINGTON AVENUE, 54TH FLOOR (Street) NEW YORK NY 10022-4629 (City) (State) (Zip) 1. Name and Address of Reporting Person* OrbiMed Genesis GP LLC (Last) (First) (Middle) 601 LEXINGTON AVENUE, 54TH FLOOR

(Street) NEW YORK	NY	10022-4629
(City)	(State)	(Zip)

Explanation of Responses:

- 1. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power over the securities held by OPI VI and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VI.
- 2. This report on Form 4 is jointly filed by GP VI, Advisors, and OrbiMed Genesis GP LLC ("Genesis GP"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
- 3. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). Genesis GP is the general partner of Genesis Master Fund and Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund.

/s/ Carl Gordon, Member of
OrbiMed Advisors LLC

/s/ Carl Gordon, Member of
the Managing Member of
OrbiMed Capital GP VI LLC
/s/ Carl Gordon, Member of
the Managing Member of
OrbiMed Genesis GP LLC

** Signature of Reporting Person

05/26/2020

05/26/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.